{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:54:36Z","timestamp":1793141676009,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7232124"],"award-info":[{"award-number":["7232124"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011176","name":"Peking Union Medical College","doi-asserted-by":"publisher","award":["PUMCSON202515"],"award-info":[{"award-number":["PUMCSON202515"]}],"id":[{"id":"10.13039\/501100011176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171800"],"award-info":[{"award-number":["82171800"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32300632"],"award-info":[{"award-number":["32300632"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371822"],"award-info":[{"award-number":["82371822"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","award":["T-B-049"],"award-info":[{"award-number":["T-B-049"]}],"id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.autrev.2025.103862","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:15:22Z","timestamp":1751382922000},"page":"103862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The efficacy and safety of monoclonal anti-TNF antibodies in the treatment of vascular Beh\u00e7et's syndrome: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"24","author":[{"given":"Yeling","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyuan","family":"Ao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2025.103862_bb0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41584-022-00880-7","article-title":"Vascular Beh\u00e7et syndrome: from pathogenesis to treatment","volume":"19","author":"Bettiol","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103862_bb0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13023-019-1061-1","article-title":"Demography of vascular Behcet\u2019s disease with different gender and age: an investigation with 166 Chinese patients","volume":"14","author":"Chen","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.autrev.2025.103862_bb0015","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00296-012-2384-6","article-title":"Behcet\u2019s disease seen in China: analysis of 334 cases","volume":"33","author":"Zhang","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2025.103862_bb0020","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1007\/s10067-020-05026-2","article-title":"Clinical manifestations of Beh\u00e7et\u2019s disease in a large cohort of Chinese patients: gender- and age-related differences","volume":"39","author":"Li","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103862_bb0025","first-page":"271","article-title":"Characteristics of death patients with Behcet\u2019 s disease (report of 24 cases)","volume":"42","author":"Jinjing","year":"2020","journal-title":"Bei Jing Yi Xue"},{"key":"10.1016\/j.autrev.2025.103862_bb0030","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/CIRCULATIONAHA.115.017738","article-title":"Neutrophil activation promotes fibrinogen oxidation and Thrombus formation in Beh\u00e7et disease","volume":"133","author":"Becatti","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2025.103862_bb0035","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jdermsci.2018.08.010","article-title":"Neutrophils contribute to vasculitis by increased release of neutrophil extracellular traps in Beh\u00e7et\u2019s disease","volume":"92","author":"Safi","year":"2018","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.autrev.2025.103862_bb0040","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1750-1172-7-20","article-title":"Beh\u00e7et\u2019s disease","volume":"7","author":"Saadoun","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.autrev.2025.103862_bb0045","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.autrev.2011.11.026","article-title":"New insights into the pathogenesis of Beh\u00e7et\u2019s disease","volume":"11","author":"Pineton de Chambrun","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103862_bb0050","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/acr.21557","article-title":"Beh\u00e7et\u2019s disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis","volume":"64","author":"Adler","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2025.103862_bb0055","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.semarthrit.2015.06.008","article-title":"Pulmonary artery involvement in Beh\u00e7et\u2019s syndrome: effects of anti-Tnf treatment","volume":"45","author":"Hamuryudan","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103862_bb0060","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2025.103862_bb0065","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003863","article-title":"Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study","volume":"95","author":"Hibi","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.autrev.2025.103862_bb0070","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.clim.2018.08.004","article-title":"Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet\u2019s disease: a multicenter observational study of 18 patients","volume":"197","author":"Desbois","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2025.103862_bb0075","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/art.40531","article-title":"Adalimumab-based treatment versus disease-modifying Antirheumatic drugs for venous thrombosis in Beh\u00e7et\u2019s syndrome: a retrospective study of seventy patients with vascular involvement","volume":"70","author":"Emmi","year":"2018","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103862_bb0080","first-page":"303","article-title":"Efficacy and safety of anti-tumor necrosis factor \u03b1 monoclonal antibodies in 16 patients with severe\/refractory vasculo Behcet\u2019s disease","volume":"59","author":"Li","year":"2020","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.autrev.2025.103862_bb0085","first-page":"1056","article-title":"Clinical analysis of golimumab in the treatment of severe\/refractory cardiovascular involvement in Behcet syndrome","volume":"52","author":"Sun","year":"2020","journal-title":"Beijing Da Xue Xue Bao"},{"key":"10.1016\/j.autrev.2025.103862_bb0090","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/1756-185X.13778","article-title":"Efficacy of TNF\u03b1 inhibitors for refractory vascular Beh\u00e7et\u2019s disease: a multicenter observational study of 27 patients and a review of the literature","volume":"23","author":"Aksoy","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103862_bb0095","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/1708538120927701","article-title":"Infliximab treatment in refractory vascular Behcet\u2019s disease: a single-center experience","volume":"28","author":"Kehribar","year":"2020","journal-title":"Vascular"},{"key":"10.1016\/j.autrev.2025.103862_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109682","article-title":"Infliximab for vascular involvement in Beh\u00e7et\u2019s syndrome","volume":"253","author":"Hatemi","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2025.103862_bb0105","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300354","article-title":"Infliximab versus cyclophosphamide for severe Beh\u00e7et\u2019s syndrome","author":"Saadoun","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.autrev.2025.103862_bb0110","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103862_bb0115","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/rheumatology\/keu233","article-title":"Vascular involvement in Beh\u00e7et\u2019s syndrome: a retrospective analysis of associations and the time course","volume":"53","author":"Tascilar","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103862_bb0120","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1002\/art.34450","article-title":"Immunosuppressants reduce venous thrombosis relapse in Beh\u00e7et\u2019s disease","volume":"64","author":"Desbois","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103862_bb0125","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000494","article-title":"Beh\u00e7et disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses","volume":"94","author":"Alibaz-Oner","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2025.103862_bb0130","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.reuma.2023.12.001","article-title":"SER recommendations on treatment of refractory Beh\u00e7et\u2019s syndrome","volume":"20","author":"Moriano Morales","year":"2024","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"10.1016\/j.autrev.2025.103862_bb0135","first-page":"2057","article-title":"Tocilizumab in the treatment of severe and\/or refractory vasculo-Beh\u00e7et\u2019s disease: a single-Centre experience in China","volume":"57","author":"Ding","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103862_bb0140","first-page":"2040","article-title":"Infliximab for parenchymal neuro-Beh\u00e7et\u2019s syndrome: case series and meta-analysis","volume":"42","author":"Wang","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2025.103862_bb0145","first-page":"1078","article-title":"International study Group for Beh\u00e7et\u2019s disease","volume":"335","author":"Criteria for diagnosis of Beh\u00e7et\u2019\u2019s disease","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103862_bb0150","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"International team for the revision of the international criteria for Beh\u00e7et\u2019s disease (ITR-ICBD). The international criteria for Beh\u00e7et\u2019s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2025.103862_bb0155","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.3390\/ijms21093072","article-title":"Beh\u04abet\u2019s disease, and the role of TNF-\u03b1 and TNF-\u03b1 blockers","volume":"21","author":"van der Houwen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2025.103862_bb0160","first-page":"1913","article-title":"Polymorphisms in the tumor necrosis factor gene and susceptibility to Behcet\u2019s disease: an updated meta-analysis","volume":"19","author":"Zhang","year":"2013","journal-title":"Mol Vis"},{"key":"10.1016\/j.autrev.2025.103862_bb0165","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s10067-015-2966-2","article-title":"Possible association of proinflammatory cytokines including IL1\u03b2 and TNF\u03b1 with enhanced Th17 cell differentiation in patients with Behcet\u2019s disease","volume":"35","author":"Shimizu","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103862_bb0170","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.4049\/jimmunol.1202677","article-title":"Role of IL-22- and TNF-\u03b1-producing Th22 cells in uveitis patients with Behcet\u2019s disease","volume":"190","author":"Sugita","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2025.103862_bb0175","doi-asserted-by":"crossref","first-page":"9261","DOI":"10.1038\/s41467-024-53528-3","article-title":"TNF inhibitors target a mevalonate metabolite\/TRPM2\/calcium signaling axis in neutrophils to dampen vasculitis in Beh\u00e7et\u2019s disease","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2025.103862_bb0180","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/jgh.15754","article-title":"The efficacy and safety of anti-tumor necrosis factor agents in the treatment of intestinal Behcet\u2019s disease, a systematic review and meta-analysis","volume":"37","author":"Zhang","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2025.103862_bb0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Minozzi","year":"2016","journal-title":"Expert Opin Drug Saf"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T22:05:30Z","timestamp":1762553130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225001223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1568997225001223"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103862","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and safety of monoclonal anti-TNF antibodies in the treatment of vascular Beh\u00e7et's syndrome: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103862"}}